Drugs / CP-PCA07
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07683013 | Jul 2026 → Sep 2027 expected | castration-resistant prostate carcinoma | Hyundai Bioscience Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CP-PCA07 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07683013 ↗ |
| Route | Oral | “CP-PCA07 will be administered orally three times daily.” NCT07683013 ↗ |